OncoMatch/Clinical Trials/NCT07092696
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Is NCT07092696 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab for cervical cancer.
Treatment: Toripalimab — To explore the efficacy and tolerability of a platinum-based regimen combined with the PD-1 antibody toripalimab administered prior to concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PD-1/PD-L1/PD-L2/CTLA-4/CD137 inhibitor or other T-cell checkpoint modulator (ipilimumab)
Prior therapy with any agent targeting PD-1, PD-L1, PD-L2, CD137, CTLA-4 (e.g., ipilimumab), or any other antibody or drug that modulates T-cell co-stimulation or checkpoint pathways.
Lab requirements
Blood counts
WBC ≥ 4 × 10⁹/L, ANC ≥ 1.5 × 10⁹/L, platelets ≥ 100 × 10⁹/L, Hb ≥ 90 g/L
Kidney function
BUN ≤ 1.5 × ULN, creatinine ≤ 1.5 × ULN
Liver function
TBIL ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN
Cardiac function
No clinically significant cardiac arrhythmias, myocardial ischemia, severe conduction block, heart failure, or severe valvular disease.
Laboratory values: WBC > 4 × 10⁹/L; platelets > 100 × 10⁹/L. Inadequate hematologic or organ function: WBC < 4.0 × 10⁹/L, ANC < 1.5 × 10⁹/L, platelets < 100 × 10⁹/L, Hb < 90 g/L; TBIL > 1.5 × ULN, ALT/AST > 2.5 × ULN, BUN > 1.5 × ULN, creatinine > 1.5 × ULN. Clinically significant cardiac arrhythmias, myocardial ischemia, severe conduction block, heart failure, or severe valvular disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify